Noreen Henig, M.D.

Noreen Henig, M.D. brings over 20 years of clinical and development leadership experience at biopharmaceutical companies, in addition to an extensive background in academic research and medicine. Dr. Henig was appointed Chief Medical Officer of Kezar Life Sciences in May 2020, and prior to that, had served as Chief Medical Officer of Breath Therapeutics since July 2018. Breath Therapeutics was acquired by Zambon SpA in July 2019 for up to 500 Million Euros and is now a Zambon Group Company. Previously, she served as Chief Development Officer of ProQR Therapeutics from 2014 to 2017, where she led preclinical and clinical development. ProQR had a successful cross-over round and IPO as a preclinical company in 2014. Earlier in her drug development career, she spent six years at Gilead Sciences, most recently as the Senior Director, Global Respiratory. Throughout her career, Dr. Henig held several senior academic positions at California Pacific Medical Center and Stanford University School of Medicine. She earned her M.D. with distinction in immunology from Albert Einstein College of Medicine and completed training in internal medicine at the University of California San Francisco, and pulmonary and critical care medicine at the University of Washington.